Pharmaceuticals

Pharmaceuticals

Southern California Biotech Company Sets New Quality Paradigm in Bio-available Innovation

Global biotech solutions company, Herbalmax Inc., announces the release of its redesigned product range for the home health nutraceutical market Irvine, Calif., April 26, 2019 /PRNewswire/ -- Herbalmax Inc. is pleased to announce the upcoming release of its refortified line of bio-available nutraceuticals led by its leading NMN (nicotinamide mononucleotide) product, Reinvigorator. In addition...

Read More »
Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994
Pharmaceuticals

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994

Cambridge, Mass., Feb. 04, 2019 (Globe Newswire) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced the acceptance by the U.S. Food and Drug Administration (FDA) of its Investigational...

Read More »
AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (Venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course
Pharmaceuticals

AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (Venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course

- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1] - Of the 130 patients who completed rituximab plus the 24-month fixed duration of venetoclax and remained off therapy for a median of 9.9 months, the...

Read More »
Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium
Pharmaceuticals

Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium

HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced detailed results of its first-in-human Phase 1 clinical trial of AVB-S6-500 in healthy volunteers. As previously announced, the trial met the safety and tolerability endpoints for the trial and demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing...

Read More »
Pharmaceuticals

AbbVie Receives Health Canada Approval of ORILISSA™ (elagolix) for the Treatment of Moderate to Severe Pain Associated with Endometriosis

Endometriosis affects up to one in 10 women of reproductive age in Canada. 7 out of 10 women being managed for endometriosis have unresolved pain throughout the month. The approval of ORILISSA is supported by data from two replicate Phase 3 studies, which evaluated nearly 1,700 women. In clinical trials, ORILISSA™demonstrated sustained relief over 12 months across the two most common types...

Read More »
Pharmaceuticals

Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA

NKTR-181 is a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy SAN FRANCISCO, July 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the treatment of chronic low...

Read More »
Pharmaceuticals

Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection

RELISTOR® Injection Protected from Generic Competition Until 2024 LAVAL, Quebec, May 2, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that the U.S. District Court for the District of New Jersey has granted a motion for partial summary judgment of validity of a formulation patent for RELISTOR® (methylnaltrexone...

Read More »
Pharmaceuticals

Northernchem Inc. Provides High-quality Research Chemicals

Canada 28-03-2017. Northernchem Inc. is the leading research chemicals supplier enables you to buy high quality pharmaceutical chemicals. These chemicals are usual for a range of purposes and will definitely suit you to get quality results. Research chemicals have very significant role in the overall process of scientific research and analysis. The superiority of this task needs efficiency of...

Read More »
Vector® Sports Training Ball Offers Visible Point of Contact
Sponsored

Vector® Sports Training Ball Offers Visible Point of Contact

Our goal is to help every athlete derive maximum enjoyment from their sport and become a better player. We offer a line of innovative training tools that combine cutting-edge technology and out of the box thinking to deliver an unbeatable competitive advantage. The Vector® Sports Training Ball is just another example of our commitment to innovation. To learn how the Vector® is helping ballplayers everywhere, see our video.

Read More »

All Topics